We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase.
- Authors
Bittencourt, H; Funke, V; Fogliatto, L; Magalhães, S; Setubal, D; Paz, A; Macedo, A V; Ruiz, J; Azambuja, A P; Silla, L; Clementino, N; Pasquini, R
- Abstract
Imatinib mesylate (IM) is now first-line treatment for CML. To study the results of treatment with IM after IFN failure/intolerance versus allogeneic BMT (allo-BMT), we retrospectively analyzed 264 patients treated for CML in first chronic phase in three different institutions. Over a 6-year period (2001–2006), 174 patients received IM after failure of or intolerance to IFN. During the same period of time, 90 patients received an allo-BMT from an HLA-matched sibling (n=83) or an unrelated donor (n=7). The IM group was older (41 versus 33 years, P<0.001). Five-year EFS was 62% among patients receiving IM and 52% among patients undergoing allo-BMT (P=0.0002). OS at 5 years was 93% for IM-treated patients and 59% for patients undergoing allo-BMT (P<0.0001). Allo-BMT cannot be considered as first-line treatment for CML patients in first chronic phase.Bone Marrow Transplantation (2008) 42, 597–600; doi:10.1038/bmt.2008.218; published online 4 August 2008
- Subjects
IMATINIB; METHANESULFONATES; BONE marrow transplantation; TRANSPLANTATION of organs, tissues, etc.; DISEASE complications
- Publication
Bone Marrow Transplantation, 2008, Vol 42, Issue 9, p597
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/bmt.2008.218